ION 440
Alternative Names: ION-440Latest Information Update: 06 Jun 2024
At a glance
- Originator Ionis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action Gene silencing; Methyl-CpG-binding protein 2 expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical X-linked genetic disorders
Most Recent Events
- 28 May 2024 Ionis Pharmaceuticals plans a phase I/II ATTUNE trial for Lubs-X-linked-mental-retardation-syndrome (In children, In adolescent, In adults, In elderly) in August 2024 (Intrathecal) (NCT06430385, EudraCT2023-507192-22, ION440CS1)
- 04 Oct 2023 Ionis Pharmaceuticals has patent protection for Methods for modulating mecp2 expression for ION 440
- 04 Oct 2023 Preclinical trials in X-linked genetic disorders in USA (unspecified route)